Recursion

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to radically improve the lives of patients and industrialize drug discovery. Our team is working to solve some of the hardest, most meaningful problems facing human health today.

Recursion is proudly headquartered in Salt Lake City, Utah with offices in Toronto, Montreal and Milpitas, California. We’re working to solve some of the most meaningful problems facing human health today. Come do the most impactful work of your career at a company that prioritizes belonging, collaboration and career development.

Recursion 101: A Biotechnology Company Industrializing Drug Discovery

41 S. Rio Grande Street
Salt Lake City, UT 84101
  • Featured Employer Badge
NEWS
Armed with a combined $850 million in cash, the companies said Thursday the resulting biotech will have a pipeline that could deliver 10 clinical readouts over the next 18 months.
Since the 2022 launch of ChatGPT, biopharma has poured money into this new form of artificial intelligence, but companies remain cautious with unproven technology.
The tech giant is investing $50 million in the Utah-based biotech to accelerate development of its AI foundation models for drug discovery.
To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now.
It was a busy week for clinical trial announcements. Here’s a look.
Fulcrum Therapeutics will launch a Phase III study of losmapimod in people with facioscapulohumeral muscular dystrophy later this year. Tonix wins Orphan Drug designation for Prader-Willi asset.
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
The year kicked off with a bang as multiple companies raced to a public listing.
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
JOBS
IN THE PRESS